Trial Profile
A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary)
- Indications Insulin resistance; Metabolic syndrome
- Focus Pharmacodynamics; Proof of concept
- Sponsors Boehringer Ingelheim
- 31 Oct 2013 Planned number of patients changed from 120 to 138 as reported by ClinicalTrials.gov.
- 06 Sep 2010 New trial record